Overview

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study

Status:
Suspended
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the antiviral efficacy, safety and tolerability of dual therapy with 3TC and DTG as initial therapy among naïve HIV patients with a documented M184V mutation.
Phase:
Phase 4
Details
Lead Sponsor:
Pedro Cahn
Collaborator:
ViiV Healthcare
Treatments:
Dolutegravir
Lamivudine